Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected].
about
Liposome-Based Adjuvants for Subunit Vaccines: Formulation Strategies for Subunit Antigens and ImmunostimulatorsGastric cancer: The times they are a-changin'Regulation of immunotherapeutic products for cancer and FDA's role in product development and clinical evaluationRestoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and PreventionEffects of chitin and sepia ink hybrid hemostatic sponge on the blood parameters of miceSafety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial.Therapeutic options for HER-2 positive breast cancer: Perspectives and future directionsRecent advances in the development of breast cancer vaccines.New Immunotherapy Strategies in Breast Cancer.Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts.Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells.Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.The immune system and inflammation in breast cancer.A plant-expressed conjugate vaccine breaks CD4(+) tolerance and induces potent immunity against metastatic Her2(+) breast cancer.Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapiesNon-clinical safety evaluation of repeated intramuscular administration of the AS15 immunostimulant combined with various antigens in rabbits and cynomolgus monkeysVaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines.Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving anticancer vaccination strategies.Recent progress concerning CpG DNA and its use as a vaccine adjuvant.Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines.Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.Selection of epitopes from self-antigens for eliciting Th2 or Th1 activity in the treatment of autoimmune disease or cancer.Trial Watch: Peptide vaccines in cancer therapy.Trial Watch: Toll-like receptor agonists for cancer therapy.Prostate cancer vaccines: an old yet novel target, the androgen receptor.Correction: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion.Translational nanoparticle engineering for cancer vaccines.Concurrent HER2 vaccination and inhibition of kinase activity: safety and immunogenicity.A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors.Recent Advances in the Treatment of Breast Cancer.
P2860
Q26765446-DD8F1877-5642-492E-A2F4-829C624B1867Q26776195-92E35A24-ACD4-4279-8C5E-1035BA1DC115Q27027876-6896C10D-4A30-499A-B95A-4D91E4FEE7C9Q28067145-C5445E89-3134-4C01-AA72-15FA5F57B503Q33575595-D231F719-DD0D-4F92-85BE-7D85EAC93279Q33653836-5B5590B1-A365-403E-8BC2-62A97E8AF354Q34023704-DF2D7C6D-10B7-42A6-B47E-28B94576B938Q34379303-1055B358-C9C0-4DE4-A2C3-0526762F03E5Q34549227-9912DD22-378A-4D51-957F-986ACB451214Q35743289-A4391E08-6CAE-433C-88F8-C9A008E221CBQ36245418-EEACE6D4-D009-4A8D-A041-EB0955655B0EQ36653524-F169DAF2-B9F1-49B8-9F4F-2D9274708380Q37033451-A4972240-498A-49C5-A6F8-D8CACDFEA41CQ37078963-9C5CCD70-B850-4152-8CC9-50500B2464F7Q37241496-2937A7DE-C048-4C24-A194-85FA91E72A46Q37275610-77766A58-A804-4853-983D-97FF70C7C901Q38076053-9436FE69-A763-440B-8CDC-5052A9E5260BQ38098973-01DD93DC-D008-466B-852B-690F52C9EAA9Q38103581-E418718C-74CF-4FF9-94BD-09535B6E76E8Q38168903-651C6F7A-49FC-4125-AA06-9E5E1A470C77Q38215394-200BB591-3159-4DD1-B610-0CB9FA86212BQ38221107-28492C08-5209-41BA-99F8-B087E7E4D15DQ38948901-BE998F8F-4B9E-4303-A04A-A8468DF41DE6Q39038768-53AACFE2-7060-45DF-B13A-12533F79EF8EQ42734544-B7AB4ABF-A5AF-4732-B95A-E394A1E268F7Q42969291-F85C461B-7135-4855-9A4B-F112ADBF1C7DQ45726626-1F625443-0C11-4C54-ABFF-019B97831246Q45847231-69D4F664-8330-4479-8BD4-837F4056FDB4Q46720677-0BEB3C21-57C2-4B5A-AFD4-09C2CF41CC23Q46757140-5EB20229-B11A-48DA-9A44-40D848E0F278Q55026505-54F13C79-0328-414A-BBF2-3109733531D2Q55353691-29241396-048A-4936-9E51-E3E3C8D5B25D
P2860
Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected].
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Phase 1 clinical trial of HER2 ...... kinase inhibition [corrected].
@ast
Phase 1 clinical trial of HER2 ...... kinase inhibition [corrected].
@en
type
label
Phase 1 clinical trial of HER2 ...... kinase inhibition [corrected].
@ast
Phase 1 clinical trial of HER2 ...... kinase inhibition [corrected].
@en
prefLabel
Phase 1 clinical trial of HER2 ...... kinase inhibition [corrected].
@ast
Phase 1 clinical trial of HER2 ...... kinase inhibition [corrected].
@en
P2093
P2860
P356
P1476
Phase 1 clinical trial of HER2 ...... kinase inhibition [corrected].
@en
P2093
Amy C Hobeika
Erika Hamilton
Frederic Lehmann
H Kim Lyerly
Henry Castro
Junping Wei
Kimberly Blackwell
Michael A Morse
Neil Spector
Takuya Osada
P2860
P2888
P356
10.1186/1479-5876-10-28
P577
2012-02-10T00:00:00Z
P5875
P6179
1045174623